BACKGROUND
Ursodeoxycholic acid (UDCA) has shown mitochondrial and neuroprotective effects and has been proposed as a treatment for Parkinson's disease (PD). However, population-level evidence on its effect on PD risk is lacking.
OBJECTIVES
To compare the risk of incident PD among UDCA initiators versus matched non-i...
C. Ju, A. Schrag, Camille B. Carroll et al.· Movement Disorders· 0 citations
Apathy is one of the most prevalent and disabling non-motor symptoms in Parkinson's disease (PD) and dementia with Lewy bodies (DLB), collectively referred to as Lewy body disorders (LBDs). It is associated with reduced quality of life, accelerated cognitive decline, increased caregiver burden, and poorer functional ou...
J. Kulisevsky, Lidia Bojtos, M. Kramberger et al.· Movement Disorders· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.